دورية أكاديمية
Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes
| العنوان: | Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes |
|---|---|
| المؤلفون: | Holman, Rury R, Bethel, M Angelyn, Mentz, Robert J, Thompson, Vivian P, Lokhnygina, Yuliya, Buse, John B, Chan, Juliana C, Choi, Jasmine, Gustavson, Stephanie M, Iqbal, Nayyar, Maggioni, Aldo P, Marso, Steven P, Öhman, Peter, Pagidipati, Neha J, Poulter, Neil, Ramachandran, Ambady, Zinman, Bernard, Hernandez, Adrian F |
| المصدر: | Journal Articles |
| بيانات النشر: | DigitalCommons@TMC |
| سنة النشر: | 2017 |
| المجموعة: | Houston Academy of Medicine-Texas Medical Center (HAM-TMC): DigitalCommons@The Texas Medical Center |
| مصطلحات موضوعية: | Aged, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Double-Blind Method, Drug Administration Schedule, Exenatide, Female, Humans, Hypoglycemic Agents, Incidence, Injections, Subcutaneous, Kaplan-Meier Estimate, Least-Squares Analysis, Male, Middle Aged, Peptides, Venoms, Medicine and Health Sciences |
| الوصف: | BACKGROUND: The cardiovascular effects of adding once-weekly treatment with exenatide to usual care in patients with type 2 diabetes are unknown. METHODS: We randomly assigned patients with type 2 diabetes, with or without previous cardiovascular disease, to receive subcutaneous injections of extended-release exenatide at a dose of 2 mg or matching placebo once weekly. The primary composite outcome was the first occurrence of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke. The coprimary hypotheses were that exenatide, administered once weekly, would be noninferior to placebo with respect to safety and superior to placebo with respect to efficacy. RESULTS: In all, 14,752 patients (of whom 10,782 [73.1%] had previous cardiovascular disease) were followed for a median of 3.2 years (interquartile range, 2.2 to 4.4). A primary composite outcome event occurred in 839 of 7356 patients (11.4%; 3.7 events per 100 person-years) in the exenatide group and in 905 of 7396 patients (12.2%; 4.0 events per 100 person-years) in the placebo group (hazard ratio, 0.91; 95% confidence interval [CI], 0.83 to 1.00), with the intention-to-treat analysis indicating that exenatide, administered once weekly, was noninferior to placebo with respect to safety (P CONCLUSIONS: Among patients with type 2 diabetes with or without previous cardiovascular disease, the incidence of major adverse cardiovascular events did not differ significantly between patients who received exenatide and those who received placebo. (Funded by Amylin Pharmaceuticals; EXSCEL ClinicalTrials.gov number, NCT01144338 .). |
| نوع الوثيقة: | text |
| وصف الملف: | application/pdf |
| اللغة: | unknown |
| العلاقة: | https://digitalcommons.library.tmc.edu/uthmed_docs/373Test; https://digitalcommons.library.tmc.edu/context/uthmed_docs/article/1372/viewcontent/nihms_1856461.pdfTest |
| الإتاحة: | https://digitalcommons.library.tmc.edu/uthmed_docs/373Test https://digitalcommons.library.tmc.edu/context/uthmed_docs/article/1372/viewcontent/nihms_1856461.pdfTest |
| رقم الانضمام: | edsbas.565F7B64 |
| قاعدة البيانات: | BASE |
| الوصف غير متاح. |